News

The Dr. Schär Nutrition Service Team is delighted to announce it has developed first and second-line dietary advice booklets for use with Irritable Bowel Syndrome (IBS) patients.

Although the gastrointestinal manifestations of GRDs are the most prevalent, a range of debilitating neurological manifestations are increasingly being recognised in clinical practice, often preceding or in the absence of gastro intestinal (GI) symptoms.

Refractory coeliac disease, a deadly form of the condition, has received its first dedicated support from NHS England with the setting up of a Rare Disease Collaborative Network (RDCN) in order to accelerate research and treatment into this life threatening condition.

We are delighted to announce that the winner of this year’s Dr Schär Institute Nutrition Project Award is Dr Leda Roncoroni from the Policlinico di Milano (University Hospital of Milan), Italy.

Glutafin’s Nutrition Service Team has produced a detailed summary of the changes proposed for gluten-free prescriptions in England and the practical implications of these across the UK. Key dates for the implementation of these changes, alongside a full list of Glutafin products and availability in England and the devolved nations are also provided here.

A significant proportion of the global population, without a medical diagnosis of coeliac disease (CD) or wheat allergy, avoid gluten or wheat in the diet.

A consensus document on role of exclusion diets in IBS has been developed to help facilitate dietary counselling in daily practice.

The prevalence of coeliac disease (CD) has rapidly increased over recent decades, but costs related to CD remain poorly quantified. The purpose of this systematic review was to assess the economic burden of CD in North America and Europe.

We are pleased to report the publication of our most recent Forum journal, a special issue dedicated to the nutritional quality and safety of manufactured gluten-free foods and implications for health and disease.